Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...

LofyGang resurfaces with LofyStealer disguised as Minecraft hack, exfiltrating IBANs and passwords to 24.152.36[.]241, ...

At TechCrunch's sold-out StrictlyVC event in San Francisco on Thursday night, we covered a lot of ground in a short time, ...

Amjad Masad said that young people who are not deeply interested in computer science should not study it.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Rendering isn’t always immediate or complete. Learn where no-JavaScript fallbacks still protect critical content, links, and ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

Fintel reports that on April 13, 2026, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 641.98% Upside As of April 9, ...

News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

After initially setting out plans to lay off dozens of workers in Massachusetts, Replimune Group is now increasing those ...